ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic cell creation by enabling simultaneous silencing of multiple gene targets while overcoming the challenges faced by existing gene editing approaches. Kili spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.Read More
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes to get them to patients, according to Patrick Hanley, PhD, chief and director of the pediatric medical center’s Cellular Therapy Program. Hanley spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco.Read More
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis, told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. However, several factors make CGTs complex, expensive, and difficult to bring to market, including small/personalized batch production and the fact that everything must be conducted in a very sterile environment.Read More
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco about how BroadOak’s medium- to long-term investment strategy sees “great science” happening in the sector that’s improving productivity and advancing cell and gene therapies (CGTs), biologics, and other modalities.Read More
ISCT working group weighs in on expanded access to CGT Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded Access Working Group, spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco about the regulatory and ethical issues around cell and gene therapy (CGT) expanded access.Read More
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’ This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT) annual meeting. ISCT President Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, spoke with ScienceBoard.net at ISCT 2022 about the status and future of the field of cell and gene therapy.Read More
ISCT22: Tackling the ethical issues around cell and gene therapy Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology at the University of Buffalo, and chair of the International Society for Cell & Gene Therapy (ISCT) Committee on the Ethics of Cell and Gene Therapy. Ikonomou spoke with ScienceBoard.net at the ISCT 2022 annual meeting in San Francisco this week.Read More
Manufacturing partnerships support high quality cell therapies Chimeric Therapeutics, Ncardia, and Novartis are some of the companies that have decided to partner to make complex manufacturing processes more efficient for novel therapies, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard.Read More
New pathology task force promoted at AACR A pathology task force has been formed with the goal of promoting pathology's role in cancer research, according to Anil Parwani, PhD, professor of pathology at The Ohio State University. Parwani shed light on the new task force in an interview with ScienceBoard.net at the recent American Association for Cancer Research (AACR) meeting in New Orleans.Read More